Aligos Therapeutics receives USD 25 million upfront in Greater China pevifoscorvir license deal with AmoytopPUBT·Jul 6 at 03:05 PMALGS-0.21%688278+7.00%
Aligos 10-K: Revenue $2.19M, EPS (2.45) — 2025 Annual FilingTradingView·Mar 5 at 07:15 AMVHT+1.16%XLV+1.27%
Asian Value Stock Picks For Intrinsic Valuation Estimates January 2026Simplywall·Jan 8 at 11:00 PM688278+7.00%002466+2.07%
3 Asian Stocks Estimated To Be 35.9% To 49.2% Below Intrinsic ValueSimplywall·Jan 5 at 10:30 PMSSNGY688278+7.00%
3 Asian Stocks Estimated To Be Undervalued In January 2026Simplywall·Jan 1 at 06:40 PM688278+7.00%600166+0.97%
Asian Market Stocks Estimated Up To 26% Below Intrinsic ValueSimplywall·Dec 9, 2025 at 01:25 AM601567+0.12%301589+3.33%
AMOYTOP released its performance for the first three quarters, with a net profit attributable to the parent company of 666 million yuan, a year-on-year increase of 20.21%Zhitong·Oct 22, 2025 at 06:21 AM688278+7.00%
AMOYTOP: The application for the marketing authorization of Pegfilgrastim for additional indications has been approvedZhitong·Oct 12, 2025 at 03:25 AM688278+7.00%
Asian Value Stocks Offering Estimated Opportunities In September 2025Simplywall·Sep 11, 2025 at 06:40 PM688278+7.00%00522+4.81%
AMOYTOP released its performance for the first half of the year, with a net profit attributable to the parent company of 428 million yuan, an increase of 40.60%Zhitong·Aug 20, 2025 at 05:48 AM688278+7.00%
Institutional consensus predicts that innovative drug concept stocks are expected to continue growing in performance over the next two yearsZhitong·Jun 8, 2025 at 11:56 PM002250+2.19%300204+2.41%
Guotai Junan Securities: Intensive Approval of Innovative Drugs, Follow-up Attention to National Procurement and National Negotiation ProgressZhitong·Jun 2, 2025 at 05:53 PM000661-0.29%688278+7.00%
